Journal of Liver

Kenichi Nakamura

Publications

• Research Article
  Prediction of Sustained Virological Response to Telaprevir/Simeprevir-Based Triple Therapy in Patients with Genotype 1 Hepatitis C Virus Using Super-Early Viral Response within 2 Weeks
  Author(s): Yoshinori Ozono, Yuka Takaishi, Mai Tsuchimochi, Kenichi Nakamura, Hiroo Abe, Tadashi Miike, Kazunori Kusumoto, Hisayoshi Iwakiri, Mitsue Sueta, Yoshihiro Tahara, Shojiro Yamamoto, Satoru Hasuike, Kenji Nagata and Kazuya ShimodaYoshinori Ozono, Yuka Takaishi, Mai Tsuchimochi, Kenichi Nakamura, Hiroo Abe, Tadashi Miike, Kazunori Kusumoto, Hisayoshi Iwakiri, Mitsue Sueta, Yoshihiro Tahara, Shojiro Yamamoto, Satoru Hasuike, Kenji Nagata and Kazuya Shimoda
  
  Objective: Rapid virological response (RVR), defined as undetectable serum hepatitis C virus (HCV) RNA at week 4, is a useful predictor of sustained virological response (SVR) to peginterferon (PEG-IFN) plus ribavirin (RBV) therapy and protease inhibitor (telaprevir (TVR)/simeprevir (SMV)) based triple therapy for patients infected with genotype 1 HCV. The aim of this study was to predict SVR using viral response within 2 weeks of therapy initiation. Methods: Fifty-two HCV genotype 1b patients with high viral loads treated with protease inhibitor (TVR/SMV)- based triple therapy were analysed. Thirty-seven patients were treated with TVR-based triple therapy and 15 with SMV-based triple therapy. HCV RNA levels were measured at the following points: the day of therapy initiation, at days 1 and 3, and at weeks 1 and 2. Results:.. View More»
  DOI: 10.4172/2167-0889.1000217

  Abstract PDF